Integration of Patient-Derived Organoids and Multiomics Profiling (IASGO 2026) - Sep 23, 2026 - Abstract #SY10-4; Pres time: Sep 9, 2026; 10:20 AM - 11:50 AM; "First-line selection between FOLFIRINOX and gemcitabine plus nab-paclitaxel still rests onage and performance status rather than tumor biology...Transcriptomic and epigenomic layers addbiology that DNA misses, yet subtyping predicts group prognosis rather than individual drug sensitivity.Direct RAS inhibition has changed this landscape: in RASolute 302, daraxonrasib doubled medianoverall survival against second-line chemotherapy...Organoids also expose vulnerabilities genomics cannot, such as MRTX1133 synergizedwith anti-EGFR agents only in KRAS G12D tumors...Co-culture with cancer-associated fibroblasts, endothelial cells, and immunecells, and microfluidic patient avatars restore these interactions. The endpoint is a patient avatar thatreconstructs the microenvironment and, read together with multiomic profiles, returns an actionablereport within a clinically useful window."
Clinical • Microsatellite Instability • Pancreatic Cancer • Solid Tumor • BRCA1 • BRCA2 • KRAS • MSI • TMB
|